FDA Approves Tisagenlecleucel for B-cell ALL, Tocilizumab for Cytokine Release Syndrome

Voice

Description

On August 30, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to tisagenlecleucel (Kymriah®, Novartis Pharmaceuticals Corp.) for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

View Article @ voice.ons.org

ONS Voice Articles

ONS's member magazine articles.

View All Voice Articles